TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23713238

Group type: EXPERIMENTAL
Intervention: Modified Banxia Houpo Decoction (MBHD)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Domperidone
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Neurostan
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Domperidone + Neurostan
Number of subjects: 89
Study: 20044757

Group type: EXPERIMENTAL
Intervention: Calcium and milk supplementation (45 g milk powder containing 350 mg calcium + 600 mg calcium/day)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Calcium and milk supplementation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 36
Study: 19832771

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 800 mg
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate 1200 mg
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 17575399

Group type: EXPERIMENTAL
Intervention: Education program for stress reduction (single-session including guidelines for worker mental health promotion, basic education lecture, and active listening training)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Education program for stress reduction
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no education program)
Number of subjects: 46
Study: 15126582

Group type: EXPERIMENTAL
Intervention: 2 or 5 mg mifepristone daily for 120 days
Number of subjects: 16
Study: 11795850

Group type: EXPERIMENTAL
Intervention: Dietary supplementation with ALNA (2 g daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dietary supplementation with FO (1 g EPA + DHA daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo oil (80:20 mix of palm and sunflowerseed oils)
Number of subjects: 0
Study: 11026996

Group type: EXPERIMENTAL
Intervention: Oral sulfasalazine (group 1)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No treatment (group 2)
Number of subjects: 22
Study: 8892775

Group type: EXPERIMENTAL
Intervention: Bunazosin (alpha-blocker)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Metoprolol (beta-blocker)
Number of subjects: 43
Study: 2070286

Group type: EXPERIMENTAL
Intervention: Propafenone (initial daily dose of 450 mg, titrated to a maximum of 900 mg per day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propafenone with the addition of a second antiarrhythmic drug
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Propafenone
Number of subjects: 40
Study: 6342407

Group type: EXPERIMENTAL
Intervention: Orthokeratology (OK) treatment group
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (conventional hard contact lenses)
Number of subjects: 80
Study: 30831344

Group type: EXPERIMENTAL
Intervention: Minipally program (intervention group)
Number of subjects: 361

Group type: COMPARATOR
Intervention: Waiting list (control group)
Number of subjects: 361
Study: 30302666

Group type: EXPERIMENTAL
Intervention: tPCNL
Number of subjects: 72

Group type: COMPARATOR
Intervention: cPCNL
Number of subjects: 72
Study: 28039705

Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 60

Group type: COMPARATOR
Intervention: Interferon-alpha (IFN-α)
Number of subjects: 60
Study: 25348257

Group type: EXPERIMENTAL
Intervention: Monofilament non‐braided suture (Ethilon)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multifilament braided suture (Mersilene tape)
Number of subjects: 0
Study: 22818539

Group type: EXPERIMENTAL
Intervention: Laparoscope cystoscopy
Number of subjects: 66

Group type: COMPARATOR
Intervention: Traditional cystoscopy
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 66
Study: 20483041

Group type: EXPERIMENTAL
Intervention: AS patients
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: ELISA verification
Number of subjects: 32

Group type: COMPARATOR
Intervention: Healthy volunteers (HVs)
Number of subjects: 32
Study: 18582259

Group type: EXPERIMENTAL
Intervention: ILMA-FOS
Number of subjects: 42

Group type: COMPARATOR
Intervention: LMA-CTrach
Number of subjects: 42
Study: 15982132

Group type: EXPERIMENTAL
Intervention: Empirical data of eye movement behavior during reading
Number of subjects: 0

Group type: COMPARATOR
Intervention: Random perturbation of the text being read
Number of subjects: 0
Study: 12570326

Group type: EXPERIMENTAL
Intervention: Unguentum Lymphaticum (UL) applied topically for 12 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 33
Study: 10512688

Group type: EXPERIMENTAL
Intervention: GHD patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study: 7727665

Group type: EXPERIMENTAL
Intervention: S. epidermidis bacteremia in the NICU
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control strains from other patients with bacteremia
Number of subjects: 56
Study: 2282994

Group type: EXPERIMENTAL
Intervention: Oral propranolol
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 145

Group type: COMPARATOR
Intervention: Conservative management (Control)
Number of subjects: 145
Study: 30683697

Group type: EXPERIMENTAL
Intervention: Abatacept treatment
Number of subjects: 0
Study: 30514400

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 750

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 750
Study: 27333006

Group type: EXPERIMENTAL
Intervention: Piezosurgery
Number of subjects: 12

Group type: COMPARATOR
Intervention: Rotary instruments
Number of subjects: 12
Study: 25299601

Group type: EXPERIMENTAL
Intervention: Whole Grain (WG) diet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Red Meat (RM) diet
Number of subjects: 20
Study: 22679525

Group type: EXPERIMENTAL
Intervention: Nitazoxanide-albendazole (1,000 mg-400 mg)
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg)
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Nitazoxanide (1,000 mg)
Number of subjects: 533

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 533
Study: 19849767

Group type: EXPERIMENTAL
Intervention: AMC/DCBA throat lozenges (n = 155)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Non‐medicated placebo lozenges (n = 155)
Number of subjects: 310
Study: 18254322

Group type: EXPERIMENTAL
Intervention: Histamine stimulating group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexamethasone group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 15563561

Group type: COMPARATOR
Intervention: Conventional HD (control)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sodium balance-positive step-down sodium profiling HD (PS)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sodium balance-neutral step-down sodium profiling HD (NS)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sodium balance-neutral alternating sodium profiling HD (NA)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Ultrafiltration only (UF only)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sodium balance-positive step-down sodium profiling HD with ultrafiltration (PS+U)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sodium balance-neutral step-down sodium profiling HD with ultrafiltration (NS+U)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sodium balance-neutral alternating sodium profiling HD with ultrafiltration (NA+U)
Number of subjects: 11
Study: 12393777

Group type: EXPERIMENTAL
Intervention: Propofol 4‐8 mg kg(‐1) h(‐1) (group P; n=16)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 1.5‐2.5 vol% sevoflurane (group S; n=17)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Both groups (Propofol and Sevoflurane)
Number of subjects: 33
Study: 10439497

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 370

Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 370
Study: 7786943

Group type: EXPERIMENTAL
Intervention: Appointment-letter invitation
Number of subjects: 757

Group type: EXPERIMENTAL
Intervention: Letter-only invitation
Number of subjects: 757

Group type: COMPARATOR
Intervention: Tagged-notes intervention
Number of subjects: 757

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 757
Study: 2187445

Group type: EXPERIMENTAL
Intervention: Single-dose prophylaxis with cefotiam and metronidazol
Number of subjects: 114

Group type: COMPARATOR
Intervention: 24-hour prophylaxis with cefotiam and metronidazol
Number of subjects: 114
Study: 6163389

Group type: EXPERIMENTAL
Intervention: Long-acting zinc-protamine-glucagon (7.5 mg every 12 hours for 4-5 days)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 31385333

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Conventional oral health education (CE)
Number of subjects: 414
Study: 28686774

Group type: EXPERIMENTAL
Intervention: Primary acne lesions (papules, pustules, comedones)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Erythematous macules or hyperpigmentation
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Papules and pustules
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Duration of papules
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Scars remaining at 6 months
Number of subjects: 32
Study: 26665288

Group type: EXPERIMENTAL
Intervention: Arm & Hammer Truly Radiant Toothpaste
Number of subjects: 182

Group type: COMPARATOR
Intervention: Colgate Cavity Protection Toothpaste
Number of subjects: 182

Group type: COMPARATOR
Intervention: Crest 3‐D White Radiant Mint Toothpaste
Number of subjects: 182
Study: 23892409

Group type: COMPARATOR
Intervention: Luminal A
Number of subjects: 3381

Group type: EXPERIMENTAL
Intervention: Triple-negative
Number of subjects: 3381

Group type: EXPERIMENTAL
Intervention: HER2-enriched
Number of subjects: 3381

Group type: COMPARATOR
Intervention: Overall population
Number of subjects: 3381
Study: 21297191

Group type: EXPERIMENTAL
Intervention: 2‐year twice‐weekly weight training intervention
Number of subjects: 0
Study: 19397667

Group type: EXPERIMENTAL
Intervention: Nonpurpuragenic pulsed dye laser (PDL)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 29
Study: 16168151

Group type: EXPERIMENTAL
Intervention: Guided Self-Help (GSH)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Delayed Treatment Control (DTC)
Number of subjects: 109
Study: 12968987

Group type: EXPERIMENTAL
Intervention: Leukotriene receptor antagonist
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 10535380

Group type: EXPERIMENTAL
Intervention: Polyunsaturated (POLY) diet
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Saturated (SAT) diet
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Monounsaturated (MONO) diet
Number of subjects: 9

Group type: COMPARATOR
Intervention: Feeding state (fed vs unfed)
Number of subjects: 9
Study: 8739862

Group type: EXPERIMENTAL
Intervention: Hot water irrigation
Number of subjects: 44

Group type: COMPARATOR
Intervention: Tamponade
Number of subjects: 44
Study: 1880439

Group type: EXPERIMENTAL
Intervention: Scopolamine Transderm-V patches
Number of subjects: 13
Study: 7102584

Group type: EXPERIMENTAL
Intervention: 7.5 g glycerol
Number of subjects: 12

Group type: COMPARATOR
Intervention: equicaloric amount of glucose solution
Number of subjects: 12

Group type: COMPARATOR
Intervention: 30 ml of water
Number of subjects: 12
Study: 31554628

Group type: EXPERIMENTAL
Intervention: Cigarette smoking
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: E‐cigarette use (vaping)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Abstention
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Variable‐power tank users
Number of subjects: 36
Study: 28665210

Group type: EXPERIMENTAL
Intervention: Universal depression screening
Number of subjects: 2494

Group type: COMPARATOR
Intervention: Routine referrals
Number of subjects: 2494
Study: 26020673

Group type: EXPERIMENTAL
Intervention: Protocol-based fluid boluses (15 mL/kg)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Fluid boluses for shock or oliguria
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Fluid responsiveness (defined as ≥ 15% increase in cardiac index)
Number of subjects: 127
Study: 23957281

Group type: EXPERIMENTAL
Intervention: Context shifts during an experience
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Across-item associative processing disruption
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Making order memory judgments
Number of subjects: 0
Study: 21685380

Group type: EXPERIMENTAL
Intervention: WM training tasks
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control tasks
Number of subjects: 48
Study: 18469279

Group type: EXPERIMENTAL
Intervention: Lutein (12 mg/d)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: DHA (800 mg/d)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Lutein + DHA
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 16554387

Group type: EXPERIMENTAL
Intervention: Aerobic exercise withdrawal (n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Continue regular exercise (n = 20)
Number of subjects: 40
Study: 15648984

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Granisetron 1 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 60
Study: 11299816

Group type: EXPERIMENTAL
Intervention: SK-1 administered intravenously at dosages of 2, 4, or 10 mg three times.
Number of subjects: 0
Study: 9165140

Group type: EXPERIMENTAL
Intervention: Megestrol acetate, 40 mg qid
Number of subjects: 129

Group type: COMPARATOR
Intervention: Cisapride, 5 mg tid
Number of subjects: 129

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 129
Study: 9582620

Group type: EXPERIMENTAL
Intervention: Chin-cap
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mandibular headgear
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 3037813

Group type: EXPERIMENTAL
Intervention: Inactivated Japanese encephalitis vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Booster dose of vaccine in the second year
Number of subjects: 0
Study: 27841057

Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery (IMR) program
Number of subjects: 198

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 198
Study: 27025442

Group type: EXPERIMENTAL
Intervention: 5 cooling sessions per day (5CS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 8 cooling sessions per day (8CS)
Number of subjects: 24
Study: 24286226

Group type: EXPERIMENTAL
Intervention: On-demand therapy for 16 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Prophylactic regimen nonacog alfa 100 IU kg(‐1) once weekly
Number of subjects: 50

Group type: COMPARATOR
Intervention: Prophylactic regimen nonacog alfa 50 IU kg(‐1) twice weekly
Number of subjects: 50
Study: 22462348

Group type: EXPERIMENTAL
Intervention: Moderate physical activity intervention group (30 subjects)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (30 subjects)
Number of subjects: 60
Study: 20675638

Group type: EXPERIMENTAL
Intervention: High-quality randomized clinical trials (RCTs) in orthopaedic surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Barriers to conducting RCTs
Number of subjects: 0
Study: 18703328

Group type: EXPERIMENTAL
Intervention: Pari Boy device with 0.4 micromol/L capsaicin
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Pari Boy device with 2.0 micromol/L capsaicin
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Maxin MA3 device with 0.06 micromol/L capsaicin
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Maxin MA3 device with 0.3 micromol/L capsaicin
Number of subjects: 65
Study: 16294204

Group type: EXPERIMENTAL
Intervention: ICG-assisted ILM peeling
Number of subjects: 24

Group type: COMPARATOR
Intervention: Triamcinolone-assisted posterior vitreous removal
Number of subjects: 24

Group type: COMPARATOR
Intervention: Comparison of both groups
Number of subjects: 24
Study: 12796769

Group type: EXPERIMENTAL
Intervention: Enalapril (mean dosage 14.6 mg, max 20 mg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Losartan (mean dosage 48 mg, max 50 mg)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 52

Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 52
Study: 10980076

Group type: EXPERIMENTAL
Intervention: Peer review meetings with feedback on prescribing behaviour for asthma treatment.
Number of subjects: 199

Group type: COMPARATOR
Intervention: Peer review meetings with feedback on prescribing behaviour for urinary tract infections (control group).
Number of subjects: 199
Study: 10213547

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (10 mg three times daily)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 218
Study: 1391262

Group type: EXPERIMENTAL
Intervention: Single dose of natural porcine surfactant (Curosurf)
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Multiple doses of natural porcine surfactant (Curosurf)
Number of subjects: 343
Study: 3755640

Group type: EXPERIMENTAL
Intervention: Atracurium 0.5 mg X kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Succinylcholine 1.0 mg X kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Atracurium 0.75 mg X kg‐1
Number of subjects: 30
Study: 29572291

Group type: EXPERIMENTAL
Intervention: MTX-hold group
Number of subjects: 316

Group type: COMPARATOR
Intervention: MTX-continue group
Number of subjects: 316
Study: 27743849

Group type: EXPERIMENTAL
Intervention: Bladder neck intussusception
Number of subjects: 48

Group type: COMPARATOR
Intervention: Nonintussusception (Control)
Number of subjects: 48
Study: 23539942

Group type: EXPERIMENTAL
Intervention: Ska game practice (50 minutes per day, three sessions per week for 16 weeks)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 40
Study: 21722894

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 4 mg daily for the first month followed by 4 mg twice daily for 11 months
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Rosiglitazone
Number of subjects: 70
Study: 19520905

Group type: EXPERIMENTAL
Intervention: Low-dose spiral computed tomography (LDCT)
Number of subjects: 2472

Group type: COMPARATOR
Intervention: Control (yearly medical examination only)
Number of subjects: 2472
Study: 17968939

Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy
Number of subjects: 31
Study: 15498545

Group type: EXPERIMENTAL
Intervention: IUGR newborns
Number of subjects: 12

Group type: COMPARATOR
Intervention: Age-matched control newborns
Number of subjects: 12
Study: 11423271

Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10(6) KIU bolus followed by 5 x 10(5) KIU/h during surgery)
Number of subjects: 38
Study: 9494025

Group type: EXPERIMENTAL
Intervention: Exercise training at 60% of peak oxygen uptake for 8 weeks
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 46
Study: 8055389

Group type: EXPERIMENTAL
Intervention: Cefotetan (2-g single dose)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Cefoxitin (standard prophylactic regimen)
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 111

Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Cefotetan and Cefoxitin
Number of subjects: 111
Study: 2662130

Group type: EXPERIMENTAL
Intervention: Terbutaline, 5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Theophylline, 200 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Combination of terbutaline and theophylline
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 31476413

Group type: EXPERIMENTAL
Intervention: Salmonella Typhi vaccination (0.025 mg; Typhim Vi, Sanofi Pasteur, UK)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 40
Study: 27527240

Group type: EXPERIMENTAL
Intervention: Amitriptyline (25, 50, 100 mg once daily at night for 1 week)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Lamotrigine (25, 50, 100 mg twice daily for 1 week)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Comparison of amitriptyline and lamotrigine
Number of subjects: 147
Study: 25428751

Group type: EXPERIMENTAL
Intervention: Endo-Sof™ double‐pigtail ureteral stent, Cook Medical
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Enhanced Durometer loop stent, Bioteq
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Polaris™ Ultra ureteral stent, Boston Scientific
Number of subjects: 90
Study: 23098325

Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol 100/10 μg
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol 250/10 μg
Number of subjects: 472

Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol (both doses)
Number of subjects: 472
Study: 21219298

Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 47
Study: 19797133

Group type: EXPERIMENTAL
Intervention: Procalcitonin group
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (antibiotic discontinuation strategy according to guidelines)
Number of subjects: 101
Study: 22372513

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) initiated at 30 mg, titrated in 20 mg increments to a maximum of 70 mg over 4-5 weeks.
Number of subjects: 28
Study: 16026400

Group type: EXPERIMENTAL
Intervention: Enoxaparin (low-molecular-weight heparin)
Number of subjects: 42

Group type: COMPARATOR
Intervention: No thrombosis prophylaxis (Control)
Number of subjects: 42
Study: 12423559

Group type: EXPERIMENTAL
Intervention: Rhodiola
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Rhodiola + Acetazolamide
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 24
Study: 9467765

Group type: EXPERIMENTAL
Intervention: Handling $500 cash in a mock budgetary task
Number of subjects: 11

Group type: COMPARATOR
Intervention: Imagining handling and budgeting the money (Control)
Number of subjects: 11